AI precision medicine company
Appears in 1 story · Last updated Oct 19, 2026
Developer of TumorSight Risk
The Food and Drug Administration cleared TumorSight Risk, the first AI tool that estimates breast cancer recurrence from an MRI a patient already has. SimBioSys's software turns routine MRI, pathology and clinical data into five- and ten-year recurrence estimates, available before surgery.
Updated Oct 19
No stories match your search
Try a different keyword
How would you like to describe your experience with the app today?
